Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE: VEEV) has acquired Veracity Logic, a cloud software provider for randomization and trial supply management (RTSM). This acquisition aims to enhance Veeva's capabilities in streamlining complex clinical trial processes. The Veeva RTSM solution has already supported 175 trials across 60 countries. The integration will be managed by Veracity's founder, Steve Zimmerman, alongside key executives. Veeva emphasizes customer choice in integrating RTSM with various systems while maintaining existing partnerships. The forward-looking statements warn of the inherent risks in acquisitions.

Veeva Systems Inc. (NYSE: VEEV) reported impressive third-quarter results for fiscal 2022, with total revenues reaching $476.1 million, a 26% year-over-year increase. Subscription services revenues also rose by 26% to $380.7 million. Operating income increased by 31% to $132.7 million, while net income grew by 9% to $105.9 million. The company provided strong guidance for the fiscal fourth quarter, projecting total revenues of $478 to $480 million and a non-GAAP net income per share of approximately $0.88. Veeva's focus on innovation and customer success positions it for continued growth.

Veeva Systems (NYSE: VEEV) introduced enhancements to Veeva CRM at the European Veeva Commercial and Medical Summit on November 18, 2021. These updates cater to the evolving dynamics of healthcare professional (HCP) engagement by providing a simplified experience for in-person and digital channels. Key features include device flexibility, role-based applications, and tailored workflows, allowing field teams to operate efficiently across various devices. Veeva CRM is utilized by 42 of the top 50 pharmaceutical firms, underscoring its industry position.

Veeva Systems announced the launch of Veeva CRM Engage Connect at the European Veeva Commercial and Medical Summit on November 18, 2021. This new feature enhances compliant messaging and content sharing for healthcare professionals (HCPs) through the Veeva Engage app, used by over one million HCPs. Engage Connect enables direct communication between HCPs and life sciences companies, providing resources and scheduling options, facilitating a more personal interaction.

Available next month, this innovation aims to improve engagement and support patient care.

On Nov. 16, 2021, Veeva Systems (NYSE: VEEV) announced that the Center for Breakthrough Medicines (CBM) adopted the Veeva Vault Quality Suite to enhance development and manufacturing services for cell and gene therapies. The partnership aims to streamline quality processes and accelerate the delivery of therapies. CBM, a CDMO, focuses on increasing access to advanced therapies. The Veeva Vault Quality Suite will enable CBM to harmonize quality processes, boost efficiency, and improve collaboration across its manufacturing network, supporting its goal of establishing a leading therapy manufacturing facility.

Veeva Systems will announce its third fiscal quarter results for 2022 on December 1, 2021, after market close. The company will hold a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. Prepared remarks will be available on its investor relations website approximately 55 minutes before the call. Veeva, a leader in cloud software for the life sciences sector, serves over 1,000 customers worldwide, including major pharmaceutical companies and emerging biotechs.

Veeva Systems (NYSE: VEEV) announced the adoption of its Vault Safety Suite by over 50 organizations, including a top global pharmaceutical company, simplifying case processing and pharmacovigilance management. The suite enhances collaboration and provides real-time safety management, benefiting sponsors and CROs with seamless adverse event processing. New features, such as a MedDRA multilingual browser and E2B import capabilities, have been added to improve efficiency. Veeva continues to commit to innovation and customer success in the life sciences industry.